<DOC>
	<DOCNO>NCT01688739</DOCNO>
	<brief_summary>The primary purpose study determine whether AMG 334 safe well tolerate healthy subject migraine patient . As part secondary objective , study conduct characterize pharmacokinetics ( PK ) profile AMG 334 single SC IV dose healthy subject migraine patient well characterize effect AMG 334 capsaicin-induced increase dermal blood flow single SC IV dose healthy subject migraine patient .</brief_summary>
	<brief_title>Ascending Single Doses AMG 334 Healthy Subjects Migraine Patients</brief_title>
	<detailed_description>In single-dose , double-blind , placebo-controlled , sequential dose escalation study , total approximately 68 subject randomize 8 cohort . Approximately 48 healthy subject randomize 6 cohort : ( 5 SC cohort 1 IV cohort ) . A total 12 migraine patient enrol cohort 7 additional 8 migraine patient may enrol optional Cohort 8 .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Healthy male female subject 18 45 year age , male female subject migraines 18 55 year age , inclusive , history evidence clinically relevant medical disorder determine investigator consultation Amgen physician ; History evidence clinically significant disorder ( include psychiatric ) , condition disease , opinion Investigator Amgen physician would pose risk subject safety interfere study evaluation , procedure , completion ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Migraine</keyword>
</DOC>